|Table of Contents|

Effect of neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and afterloading on stage ⅢC cervical cancer

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2024 17
Page:
3275-3280
Research Field:
Publishing date:

Info

Title:
Effect of neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and afterloading on stage ⅢC cervical cancer
Author(s):
CHEN Min; ZHOU Hang; LIU Xiao; YANG Shu; ZHANG Xiaolin; PENG Rui; HUANG Dan
Department of Abdominal Oncology,the Second Affiliated Hospital of Zunyi Medical University,Guizhou Zhunyi 563099,China.
Keywords:
cervical cancer; ⅢC stage; neoadjuvant chemotherapy; concurrent radiotherapy and chemotherapy; afterloading therapy; short-term curative effect; long-term curative effect; adverse effect
PACS:
R737.33
DOI:
10.3969/j.issn.1672-4992.2024.17.018
Abstract:
Objective:To observe the efficacy and safety of neoadjuvant chemotherapy combined with concurrent radiotherapy and chemotherapy and afterloading in the treatment of stage ⅢC cervical cancer.Methods:100 patients with stage ⅢC cervical cancer from January 2020 to December 2022 were selected and divided into observation group and control group according to different treatment schemes,with 50 cases in each group.The observation group was treated with neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and afterloading,while the control group was treated with concurrent chemoradiotherapy combined with afterloading.The short-term and long-term curative effects of the two groups were compared,and the safety of the two schemes in the treatment of stage ⅢC cervical cancer was observed.Results:The total effective rate of the observation group was 94.00%,which was higher than that of the control group(80.00%),with statistical significance(P＜0.05).The distant metastasis rate in the observation group was lower than that in the control group,and the difference was statistically significant(P＜0.05).The adverse reactions of the two groups were graded as 1-2,which did not affect the related treatment.There was no significant difference in the total incidence of adverse reactions between the two groups(P＞0.05).Conclusion:Neoadjuvant chemotherapy combined with concurrent chemoradiotherapy and brachytherapy for stage ⅢC cervical cancer can achieve ideal short-term and long-term effects,reduce the risk of distant metastasis,and have mild adverse reactions,high safety and clinical application value.

References:

[1] 王悠清.2020年全球癌症统计报告［J］.中华预防医学杂志,2021,55(3):398-398. WANG YQ.2020 Global cancer statistics report［J］.Chinese Journal of Preventive Medicine,2021,55(3)：398-398.
[2] 陈号,夏昌发,由婷婷,等.中国女性宫颈癌负担快速上升的原因及其应对措施［J］.中华流行病学杂志,2022,43(5):761-765. CHEN H,XIA CF,YOU TT,et al.The reasons for the rapid increase in the burden of cervical cancer among Chinese women and their corresponding measures［J］.Chinese Journal of Epidemiology,2022,43(5)：761-765.
[3] 唐丹,郄明蓉.2019年美国阴道镜和子宫颈病理学会子宫颈癌筛查和管理指南在中国的参考意义和启示［J］.实用妇产科杂志,2021,37(12):904-906. TANG D,XI MR.The reference significance and inspiration of the 2019 American Society of Colposcopy and Cervical Pathology Cervical Cancer Screening and Management Guidelines in China［J］.Journal of Practical Obstetrics and Gynecology,2021,37(12)：904-906.
[4] BEREK JS,MATIAS-GUIU X,CREUTZBERG C,et al.FIGO staging of endometrial cancer：2023［J］.Int J Gynaecol Obstet,2023,162(2):383-394.
[5] DUAN H,LI H,KANG S,et al.Rationality of FIGO 2018 ⅢC restaging of cervical cancer according to local tumor size：A cohort study［J］.Acta Obstet Gynecol Scand,2023,102(8):1045-1052.
[6] YE Y,ZHANG G,LI Z,et al.Initial treatment for FIGO 2018 stage ⅢC cervical cancer based on histological type：A 14-year multicenter study［J］.Cancer Med,2023,12(19):19617-19632.
[7] 张菁霓,蔡晶,王泽华.局部晚期子宫颈癌新辅助化疗的争议及现状［J］.中国实用妇科与产科杂志,2023,39(7):677-683. ZHANG JN,CAI J,WANG ZH.Neoadjuvant chemotherapy for locally advanced cervical cancer:controversies and current status［J］.Chinese Journal of Practical Gynecology and Obstetrics,2023,39(7):677-683.
[8] MEREU L,PECORINO B,FERRARA M,et al.Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer：Retrospective single-center study［J］.Cancers(Basel),2023,15(21):5207.
[9]雷磊，王国庆，孟龄婷，等.新辅助化疗联合宫颈癌根治术治疗局部晚期宫颈癌的疗效及安全性分析［J］.现代肿瘤医学，2020,28（22）：3959-3962. LEI L,WANG GQ,MENG LT,et al.Analysis of the efficacy and safety of neoadjuvant chemotherapy combined with radical cervical cancer in the treatment of locally advanced cervical cancer［J］.Modern Oncology，2020,28（22）：3959-3962.
[10] MARTH C,LANDONI F,MAHNER S,et al.Cervical cancer：ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up［J］.Ann Oncol,2017,28(4):72-83.
[11] SCHARL S,WEIDENBAECHER CB,HUGO C,et al.First experiences with PET-MRI/CT in radiotherapy planning for cervical cancer［J］.Arch Gynecol Obstet,2022,306(5):1821-1828.
[12] LI J,LI Y,WANG H,et al.Neoadjuvant chemotherapy with weekly cisplatin and paclitaxel followed by chemoradiation for locally advanced cervical cancer［J］.BMC Cancer,2023,23(1):51.
[13] JI L,ZHANG W,HAO S,et al.Clinical efficacy analysis of radioactive 125I particle implantation for the treatment of pelvic local recurrence of cervical cancer after radiotherapy［J］.J Contemp Brachytherapy,2023,15(6):432-441.
[14] SHAN Y,DING Z,CUI Z,et al.Incidence,prognostic factors and a nomogram of cervical cancer with distant organ metastasis：a SEER-based study［J］.J Obstet Gynaecol,2023,43(1):2181690.
[15] WEI C,XIANG X,ZHOU X,et al.Development and validation of an interpretable radiomic nomogram for severe radiation proctitis prediction in postoperative cervical cancer patients［J］.Front Microbiol,2023,13(4):1090770.
[16] WU Y,LI P,ZHU Y,et al.Effectiveness and safety of mono-anlotinib mono therapy or in combination with chemotherapy in platinum-resistant recurrent ovarian cancer：a single-center retrospective study［J］.Am J Transl Res,2023,15(3):1973-1981.
[17] SINGH D,VIGNAT J,LORENZONI V,et al.Global estimates of incidence and mortality of cervical cancer in 2020：a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative［J］.Lancet Glob Health,2023,11(2):e197-e206.
[18] COHEN CM,WENTZENSEN N,CASTLE PE,et al.Racial and ethnic disparities in cervical cancer incidence,survival,and mortality by histologic subtype［J］.J Clin Oncol,2023,41(5):1059-1068.
[19] 王琼.多部门联合印发《加速消除宫颈癌行动计划(2023-2030年)》:推进宫颈癌防治体系建设,加快宫颈癌消除进程［J］.妇儿健康导刊,2023,2(6):6. WANG Q.Multiple departments jointly issued the "Action Plan for Accelerating the Elimination of Cervical Cancer(2023-2030)"：Promoting the Construction of Cervical Cancer Prevention and Control System,Accelerating the Process of Cervical Cancer Elimination［J］.Women and Children's Health Guide,2023,2(6)：6.
[20] 蔡会龙,原伟光,孙惠昕.全球及我国宫颈癌流行现状及防治策略［J］.临床肿瘤学杂志,2023,28(1):90-93. CAI HL,YUAN WG,SUN HX.Prevalence and prevention strategies of cervical cancer in the world and China［J］.Chinese Clinical Oncology,2023,28(1):90-93.
[21] SOARES LC,DE SOUZA RJ,OLIVEIRA MAP.Reviewing FIGO 2018 cervical cancer staging［J］.Acta Obstet Gynecol Scand,2023,102(12):1757-1758.
[22] 高毓,陈敏,向清明,等.螺旋断层放疗与调强放疗在宫颈癌中剂量学及安全性对比的Meta分析［J］.武汉大学学报:医学版,2023,44(7):833-840. GAO Y,CHEN M,XIANG QM,et al.Meta analysis on dosimetric and toxicity comparison between tomotherapy and intensity modulated radiotherapy for cervical cancer［J］.Medical Journal of Wuhan University,2023,44(7):833-840.
[23] 杨杰,郭丽宁,许汴菊.CT引导下三维腔内后装放疗联合体外调强化疗在治疗晚期宫颈癌的应用价值［J］.中国医学物理学杂志,2022,39(10):1213-1216. YANG J,GUO LN,XU BJ.The application value of CT guided three-dimensional intracavitary radiotherapy combined with extracorporeal intensity modulated chemotherapy in the treatment of advanced cervical cancer［J］.Chinese Journal of Medical Physics,2022,39(10)：1213-1216.
[24] LI W,LIU P,HE F,et al.The long-term outcomes of clinical responders to neoadjuvant chemotherapy followed by radical surgery in locally advanced cervical cancer［J］.J Cancer Res Clin Oncol,2023,149(8):4867-4876.
[25] 党洁,渠淑云,翟瑶,等.术前新辅助化疗联合腔内后装放疗治疗局部晚期宫颈癌的临床疗效及对患者预后的影响［J］.癌症进展,2023,21(10):1141-1143. DANG J,QU SY,ZAI Y,et al.Clinical efficacy of preoperative neoadjuvant chemotherapy combined with intracavitary afterloading radiotherapy in patients with locally advanced cervical cancer and its impact on prognosis［J］.Oncology Progress,2023,21(10):1141-1143.
[26] 吴达莹,姜瑶,李贵玲.子宫颈癌化学治疗进展［J］.中国癌症防治杂志,2023,15(5):492-498. WU DY,JIANG Y,LI GL.Progress of chemotherapy for cervical cancer［J］.Chinese Journal of Oncology Prevention and Treatment,2023,15(5):492-498.

Memo

Memo:
贵州省科技计划项目（编号：2019-4433）;贵州省卫生健康委科学技术基金项目（编号：WJW-2023-004）
Last Update: 2024-07-31